Compare ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares UltraShort Bloomberg Natural Gas ETF vs State Street SPDR S&P Biotech ETF — how do they compare? ProShares UltraShort Bloomberg Natural Gas ETF trades at $28.67, while State Street SPDR S&P Biotech ETF trades at $159.4. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, ProShares UltraShort Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals.
| KOLD | XBI | |
|---|---|---|
Sector | Leveraged / Inverse | Broad Market / Factor |
52-Week High | $49.39 | $164.28 |
52-Week Low | $13.58 | $86.92 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KOLD trades at $28.54, down 0.35% on the day, with technical indicators showing a bullish bias from moving averages while oscillators remain neutral. The ETF tracks natural gas price movements inversely, with recent news highlighting volatility in natural gas markets driven by weather patterns and LNG demand. Support levels cluster around $28 with resistance at $29-$30.
As a leveraged ETF, KOLD carries significant volatility risks and is designed for short-term trading rather than long-term investment. The natural gas market faces headwinds from production levels and storage data, while geopolitical developments and weather patterns create trading opportunities for tactical investors.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
